Open AccessPasireotide treatment in Cushing's disease: A single tertiary center's experience
Author(s) -
SERDAR ŞAHİN,
GULAR KARİMOVA,
Şeyda Gül Özcan,
EMRE DURCAN,
HANDE MEFKURE ÖZKAYA,
Pınar Kadioğlu
Publication year - 2022
Publication title -
turkish journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.277
H-Index - 27
eISSN - 1303-6165
pISSN - 1300-0144
DOI - 10.55730/1300-0144.5335
Subject(s) - medicine , pasireotide , adverse effect , cushing's disease , gastroenterology , acromegaly , endocrinology , disease , hormone , growth hormone
Patients who were followed up for CD and treated with pasireotide between 2014-2020 at Cerrahpaşa Medical Faculty, were evaluated retrospectively. The efficacy and adverse effects of pasireotide were evaluated in this study.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom